- Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui’s ongoing, multi-site, open label Phase 1 trial
- Data will include patients from the dose escalation and at multiple expansion doses
- U.S. Phase 1 trial of IDE849 in SCLC patients initiated in 3Q 2025
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, today announced the publication of an abstract for an oral presentation on IDE849 (SHR-4849) at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (WCLC), taking place September 6-9, 2025 in Barcelona, Spain. The presentation will cover efficacy and safety results in SCLC from the Phase 1 trial Hengrui is conducting in China for IDE849 (SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topoisomerase-1 (TOP1) payload antibody drug conjugate (ADC). DLL3 is upregulated across multiple solid tumor types where significant unmet need remains, including SCLC, neuroendocrine tumors (NETs), non-small cell lung cancer (NSCLC) and melanoma.
IDEAYA will also have a poster presentation with data from a second published abstract providing combination mechanism and pre-clinical synergy data between TOP1-payload based ADCs and IDE161, the company’s proprietary, potentially first-in-class PARG inhibitor. This combination has the potential to enhance the durability of TOP1-payload based ADCs, including IDE849 and IDE034, IDEAYA’s B7H3/PTK7 bispecific TOP1 ADC, and aligns with the company’s clinical development strategy of evaluating rational combinations, where appropriate, to drive improved clinical outcomes for patients with cancer.
“We are excited to have the first-in-human Phase 1 clinical efficacy and safety data presented by our partner Hengrui for IDE849 (SHR-4849) in SCLC patients at the WCLC 2025, as IDEAYA rapidly advances the global development of IDE849,” said Dr. Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences. “IDE849 represents a potential first-in-class DLL3-TOP1 ADC, and we look forward to evaluating its clinical potential as both a monotherapy agent in SCLC and NET patients, as well as in combination with immunotherapy and our Phase 1 PARG inhibitor, IDE161,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.
Details of the oral presentation are as follows:
Title: A first-in-human Phase 1 study of SHR-4849 (IDE849), a DLL3-directed antibody drug conjugate (ADC) in relapsed SCLC
Date and time: Sunday, September 7th, 4:45-6:00 PM (CET)
Session: OA6 – Novel ADCs in SCLC
Details of the poster presentation are as follows:
Control #: 2165
Title: Dual PARG-TOP1 Inhibition Exacerbates DNA-Protein Crosslinks and Replication Stress: A Promising Strategy for Enhancing TOP1i-ADC Efficacy
Presenter: Reeja Maskey, Ph.D.
Date and time: Monday September 8th, 10:30 AM – 12:00 PM (CET)
Session: P2.10 – Metastatic Non-small Cell Lung Cancer – Antibody-Drug Conjugate and Cytotoxic Therapy
The oral presentation and poster will be available online at https://ir.ideayabio.com/events following the presentation.
